MondayApr 08, 2019 11:46 am

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Collaborators Report Positive Preclinical Data at 2019 AACR Annual Meeting

Clinical-stage gene therapy company Genprex Inc. (NASDAQ: GNPX) this morning announced that its collaborators from the University of Texas MD Anderson Cancer Center (“MD Anderson”) detailed positive preclinical data, in a poster presented at the American Association of Cancer Research Meeting 2019, regarding the combination of the TUSC2 gene with an anti-PD1 antibody, pembrolizumab, for the treatment of lung cancer. TUSC2 is a tumor suppressor gene and the active agent in Genprex’s Oncoprex immunogene therapy. “Development of an improved humanized patient-derived xenograft, Hu-PDX, mouse model for evaluation of antitumor immune response in lung cancer,” was the title of the poster,…

Continue Reading

TuesdayApr 02, 2019 9:53 am

BioMedNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Posts Clinical, Corporate and Financial Update

Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) on Monday provided a clinical, corporate and financial update for the year ended December 31, 2018. Among other highlights, Genprex reached various milestones in 2018 and early 2019 which included completing its initial public offering (“IPO”) and listing of common stock on NASDAQ Capital Market, completing a $10 million private placement, and securing a contract with Accenture to provide clinical data management services to help fast-track the clinical development of Oncoprex(TM). “Over the past year, we made great progress in advancing the development of our gene therapy platform, including Oncoprex(TM) immunogene therapy for…

Continue Reading

ThursdayMar 14, 2019 11:53 am

BioMedNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) to Present at Seventh Annual ARM Cell & Gene Therapy Investor Day in New York City

Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) this morning announced that it will be presenting at the upcoming ARM Cell & Gene Therapy Investor Day, hosted by the Alliance for Regenerative Medicine, to be held in New York City on March 21, 2019. Unique to the medical and biotech communities, the investor conference focuses on fast-paced, concise presentations from more than 35 companies, consolidated to a one-day conference while allowing opportunities for one-on-one partnering with venture and strategic investors. Genprex’s presentation is scheduled for Thursday, March 21, at 2:30-2:45 p.m. EDT in the Main Bar Room of the Metropolitan Club,…

Continue Reading

ThursdayMar 07, 2019 9:34 am

BioMedNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Names New Additions to Senior Team

Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) announced on February 27 that it has hired Eric Chapdelaine, Senior Director of Pharmaceutical Sciences and Manufacturing, and Kalyn Dabbs, Senior Manager of Communications and Marketing. The move to grow the company’s senior team is in accordance with Genprex’s preparation to expand its operations and focus on corporate communications in 2019. Chapdelaine will be tasked with overseeing analytical development, chemistry, manufacturing and controls, technical operations and supply chain management for the company. Dabbs will oversee the development and implementation of internal and external communication and marketing plans as well as managing the company’s…

Continue Reading

BioMedWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 415.949.5050